[Cited FineTest Antibody] Current Research on Atherosclerosis Treatment

FineTest antibody contributes to the research on atherosclerosis treatment. The immunofluorescence is designed to measure TLR4 and F4/80 in BMDMs cell.

Publication Details
Article Title: LPS adsorption and inflammation alleviation by polymyxin B-modified liposomes for atherosclerosis treatment
Journal Title: Acta Pharmaceutica Sinica B
DOI: 10.1016/j.apsb.2023.06.005
IF: 14.907

Abstract: Chronic inflammation is critical in the onset and progression of atherosclerosis (AS). The lipopolysaccharide (LPS) level in the circulation system is elevated in AS patients and animal models, which is correlated with the severity of AS. Inspired by the underlying mechanism that LPS could drive the polarization of macrophages toward the M1 phenotype, aggravate inflammation, and ultimately contribute to the exacerbation of AS, LPS in the circulation system was supposed to be the therapeutic target for AS treatment. In the present study, polymyxin (PMB) covalently conjugated to PEGylated liposomes (PLPs) were formulated to adsorb LPS through specific interactions between PMB and LPS. In vitro, the experiments demonstrated that PLPs could absorb LPS, reduce the polarization of macrophages to M1 phenotype and inhibit the formation of foam cells. In vivo, the study revealed that PLPs treatment reduced the serum levels of LPS and pro-inflammatory cytokines, decreased the proportion of M1-type macrophages in AS plaque, stabilized AS plaque, and downsized the plaque burdens in arteries, which eventually attenuated the progression of AS. Our study highlighted LPS in the circulation system as the therapeutic target for AS and provided an alternative strategy for AS treatment.

Keywords: Lipopolysaccharide, Atherosclerosis, Polymyxin, Liposomes, Macrophages

Immunofluorescence

Validated Image

Figure Source: Acta Pharm Sin B. 2023 doi: 10.1016/j.apsb.2023.06.005.